Department of
Medical Ethics and Health Policy
Medical Ethics and Health Policy
Department of Medical Ethics / People / Lynch
Holly Fernandez Lynch JD, MBE
Associate Professor of Medical Ethics and Health Policy at the Hospital of the University of Pennsylvania
Department: Medical Ethics and Health Policy
Contact information
Blockley Hall, Room 1426
423 Guardian Drive
Philadelphia, PA 19104
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-746-7327
Links
Public website for the Advancing Effective Research Ethics Oversight (AEREO) Consortium
A resource for locating diverse, underrepresented bioethics scholars
Public website for the Advancing Effective Research Ethics Oversight (AEREO) Consortium
A resource for locating diverse, underrepresented bioethics scholars
Education:
BA (Health and Societies)
University of Pennsylvania College of Arts and Sciences, 2003.
JD (Law)
University of Pennsylvania Law School, 2006.
MBE (Bioethics)
University of Pennsylvania School of Medicine, 2006.
Permanent linkBA (Health and Societies)
University of Pennsylvania College of Arts and Sciences, 2003.
JD (Law)
University of Pennsylvania Law School, 2006.
MBE (Bioethics)
University of Pennsylvania School of Medicine, 2006.
Selected Publications
Lynch HF, Tillman I, Summers E, Mah E: Viewpoint: Preserving Research Ethics Oversight Amid Decimation of the Research Enterprise. JAMA Online first 2025 Notes: Peer reviewed.Zettler P, Sachs RE, Joffe S, Lynch HF: Viewpoint: The Dangers of Decoupling Safety and Effectiveness in Drug Approval. JAMA Online first 2025 Notes: Peer reviewed.
Sliwinski K, Miller J, Lynch HF: Equity-Related Eligibility Criteria in Trials Supporting 2022 US Drug Approvals. PLOS One In press 2025.
Kurian M, Ferrell W, Ulloa Perez E, Hubbard R, Joffe S, Mamtani R, Parikh RB, Lynch HF: Specificity of Food and Drug Administration Postmarketing Requirements and Associations with Timely Submissions and Regulatory Decisions for Oncology Accelerated Approvals, 2011-2023: A Cross-Sectional Analysis. BMJ Oncology In press 2025.
Friends of Cancer Research/Parker Institute for Cancer Immunotherapy: Regulatory and Manufacturing Pathways to Expand Access to Genetically Modified Cell-Based Therapies. White Paper 2025 Notes: https://friendsofcancerresearch.org/wp-content/uploads/Regulatory-and-Manufacturing-Pathways-to-Expand-Access-to-Genetically-Modified-Cell-Based-Therapies.pdf.
Parikh RB, Perez EU, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R: Prescribing Changes in Response to US Food and Drug Administration Accelerated vs. Regular Approval of Oncology Therapies. JAMA Network Open In press 2025.
Hu X, Robertson C, Bateman-House A, Lynch HF: Balancing Scientific Uncertainty and Demand for Psychedelic Medicines (chapter). Law and Policy of Psychedelic Medicine. Cohen IG, Marks M, McGuire AL (eds.). Cambridge University Press, In press 2025.
Greenberg KG, Lynch HF, Nwakama C, Frumovitz J, Setru S, Johnson AM, Shah SM, Schadt L, McCoy MS, Hoffman AK, Largent EA: A Review of Public Comments Submitted to the Centers for Medicare and Medicaid Services in Response to the 2022 National Coverage Decision on Treatment for Alzheimer’s Disease. Journal of Law & Biosciences 12(1): lsaf004, 2025.
McCoy M, Gaines M, Joffe S, Kanter GP, Largent EA, Lo B, Lynch HF, Whelan AM, Mello MM: A Framework for Assessing the Permissibility of Academic Leaders’ Outside Activities. Milbank Quarterly In press 2025.
Lynch HF, Kramer DB: Editorial: Facilitating Efficient and Ethical Trials at the Intersection of Research and Clinical Care. JAMA 333(1): 34-36, 2025.